SorLA modulates atheroprotective properties of CLA by regulating monocyte migration

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 400-407

  McCarthy, Cathal ^a   O'Gaora, Peadar ^a   James, William G ^a   McClelland, Sarah ^a   Fitzgerald, Desmond J ^a   Belton, Orina ^a   de Gaetano, Monica ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Conjugated linoleic acid; Monocyte migration; Peroxisome proliferator activator receptor gamma (PPARy); SorLA

Indexed keywords

15 DEOXY PROSTAGLANDIN; CONJUGATED LINOLEIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RECEPTOR; SORTILIN; SORTILIN RELATED RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURAL HOMOLOGY;

ANIMALS; ATHEROSCLEROSIS; CELL MOVEMENT; CHEMOKINE CCL2; CHROMANS; HUMANS; LINOLEIC ACIDS, CONJUGATED; MEMBRANE TRANSPORT PROTEINS; MICE; MONOCYTES; PPAR GAMMA; RECEPTORS, LDL; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THIAZOLIDINEDIONES;

EID: 78649727115     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.025     Document Type: Article

References (28)

1. Bhattacharya A., Banu J., Rahman M., Causey J., Fernandes G. Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem 2006, 17:789-810.
2. Churruca I., Fernandez-Quintela A., Put Portillo M. Conjugated linoleic acid isomers: differences in metabolism and biological effects. BioFactors 2009, 35(1):105-111.
3. Toomey S., Harhen B., Roche H.M., Fitzgerald D., Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 2006, 187:40-49.
4. McClelland S., Cox C., O'Connor R., et al. Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell. Atherosclerosis 2010, 211(1):96-102.
5. McCarthy C., Cox C., Belton O. Conjugated linoleic acid reduces expression of migratory regulator SORL1 in the vasculature. Atherosclerosis Suppl 2009, e1-e11715.
6. Li A.C., Brown K.K., Silvestre M.J., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106:523-531.
7. Chen Z., Ishibashi S., Perrey S., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotrophic effects omn CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372-377.
8. Nakaya H., Summers B.D., Nicholson A.C., et al. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPAR{gamma} ligand pioglitazone. Am J Pathol 2009, 174:2007-2014.
9. Yamazaki H., Bujo H., Kusunoki J., et al. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J Biol Chem 1996, 271:24761-24768.
10. Gliemann J., Hermey G., Nykjaer A., et al. The mosaic receptor SorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalisation of bound ligand. Biochem J 2004, 381:203-212.
11. Hiltunen T.P., Luoma J.S., Nikkari T., Yla-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998, 97:1079-1086.
12. Lusis A.J. Atheroslerosis. Nature 2000, 407:233-241.
13. Charo I.F., Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858-866.
14. Jacobsen L., Madsen P., Jacobsen C., et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem 2001, 276(25):22788-22796.
15. Zhu Y., Bujo H., Yamazaki H., et al. LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ Res 2004, 94:752-758.
16. Wang S.S., Shi W., Wang X., et al. Mapping, genetic isolation, and characterisation of loci that determine resistance to atherosclerosis in C3H mice. Arterioscler Thromb Vasc Biol 2007, 27:2671-2676.
17. Zhu Y., Bujo H., Yamazaki H., et al. Enhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitro. Circulation 2002, 105:1830-1836.
18. Hermey G. The Vps10p-domain receptor family. Cell Mol Life Sci 2009, 66:2677-2689.
19. Linsel-Nitschke P., Heeren J., Aherrahrou Z., et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 2010, 208(1):183-189.
20. Haidar B., Kiss R.S., Sarov-Blat L., et al. A lysosomal protease regulates ABCA-1 mediated lipid efflux. J Biol Chem 2006, 281(52):39971-39981.
21. Kanaki T., Bujo H., Hirayama S., et al. Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999, 19:2687-2695.
22. Zhu Y., Bujo H., Yamazaki H., et al. an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ Res 2004, 94:752-758.
23. Gauthier A., Vassiliou G., Benoist F., McPherson R. Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor γ. J Biol Chem 2003, 278(14):11945-11953.
24. Bujo H., Saito Y. Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family. Arterioscler Thromb Vasc Biol 2006, 26:1246-1252.
25. Ohwaki K., Bujo H., Jiang M., et al. A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages. Arterioscler Thromb Vasc Biol 2007, 27:1050-1056.
26. Weaver A.M., Husssaini I.M., Mazar A., Henkin J., Gonias S.L. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem 1997, 272:14372-14379.
27. Gyetko M.R., Todd R.F., Wilkinson C.C., Sitrin R.G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994, 93:1380-1387.
28. Nakayama M., Yoshida E., Sugiki M., et al. Up-regulation of the urokinase-type plasminogen activator receptor by monocyte chemotactic proteins. Blood Coagul Fibrinolysis 2002, 13(5):383-391.